Core Viewpoint - Cibus, Inc. has announced a securities purchase agreement to sell 9,040,000 shares of Class A Common Stock at a price of $2.50 per share, aiming to raise approximately $22.6 million for further development of its agricultural biotechnology pipeline and general corporate purposes [1][2]. Group 1: Offering Details - The offering includes pre-funded warrants and warrants to purchase an aggregate of 9,040,000 shares of Class A Common Stock, with the warrants exercisable upon stockholder approval at a price of $2.50 per share [1]. - The gross proceeds from the offering are expected to be around $22.6 million before deducting fees and expenses, with the offering anticipated to close on or about January 24, 2025 [2]. - A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering [3]. Group 2: Investor Warrants - Certain investors in the offering hold outstanding warrants to purchase up to 1,198,040 shares of Class A Common Stock, with the exercise price being reduced from $10.00 to $2.50 per share [4]. - The threshold for the redemption provision of the Investor Warrants has been lowered to $5.00 per share, and the termination date has been extended to five years following the closing of the offering [4]. Group 3: Company Overview - Cibus is a leader in gene editing technology focused on developing productivity traits for major global row crops, addressing challenges such as diseases and pests that cost the global economy approximately $300 billion annually [7]. - The company is not a seed company but a technology company that licenses traits to seed companies in exchange for royalties on seed sales [7]. - Cibus has developed a pipeline of five productivity traits, with some traits already in commercial development with leading seed companies [8].

SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced it has entered into securities purchase agreements with existing investors of the Company, including institutional and strategic investors, as well as with the Company’s CEO, Rory Riggs, for the purchase and sale of 9,040,000 share ...

Culmination of Advances in Gene Editing Efficiency and Process Improvements Drives Standardization of Cibus’ Gene Editing System Delivering Traits in a Customer’s Elite Germplasm in less than 12 Months Cibus Announces Editing Milestone in the Continuing Development of its Soybean Platform SAN DIEGO, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced th ...

Culmination of Advances in Gene Editing Efficiency and Process Improvements Drives Standardization of Cibus' Gene Editing System Delivering Traits in a Customer's Elite Germplasm in less than 12 Months Cibus Announces Editing Milestone in the Continuing Development of its Soybean Platform SAN DIEGO, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced tha ...

Core Insights - Cibus, in collaboration with Albaugh and RTDC, is advancing the commercialization of its Clethodim-tolerant HT-3 rice trait, aimed at providing a new weed management solution for U.S. rice farmers [1][2][3] - The HT-3 trait is a significant breakthrough in herbicide tolerance, expected to be the first of several stacked traits for improved weed management in rice [2] - Cibus is currently working with four seed partners for the HT-3 trait, including two in the U.S. and two in South America, and is in discussions with major rice seed companies in Asia [2] Company Overview - Cibus is a technology company specializing in gene editing to develop and license plant traits, focusing on productivity traits for major global row crops such as rice, canola, and soybean [4] - The company aims to address critical productivity and sustainability challenges for farmers, with an estimated global economic cost of $300 billion annually due to diseases and pests [4] - Cibus has a pipeline of five productivity traits, including those for weed management in rice, pod shatter reduction, and disease resistance [4]

Core Insights - Cibus, in collaboration with Albaugh and RTDC, is advancing the commercialization of its Clethodim-tolerant HT-3 rice trait, aimed at providing a new weed management solution for U.S. rice farmers [1][2][3] - The HT-3 trait is a significant breakthrough in herbicide tolerance, expected to be the first of several stacked weed management traits for rice, with four current seed partners and discussions ongoing with major rice seed companies in Asia [2][3] Company Overview - Cibus is a technology company specializing in gene editing to develop and license plant traits, focusing on productivity traits for major global row crops like canola, rice, and soybean [4] - The company aims to address critical agricultural challenges, with a pipeline that includes five productivity traits, particularly in weed management for rice [4]

Cibus and Biographica to collaborate on identifying gene editing targets for Cibus’ disease resistance trait development Biographica’s proprietary AI platform linked with Cibus’ crop editing abilities provide opportunities for discovery and commercial application SAN DIEGO and LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, and Biographica, a UK-based leader in AI and grap ...

SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, will participate in the 13th Annual Roth Technology Conference. The conference is being held in New York City on November 19-20, 2024. Cibus is available for meetings on both days of the conference. Conference attendees shou ...

Cibus, Inc. (NASDAQ:CBUS) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Carlo Broos - Chief Financial Officer Rory Riggs - Co-Founder, Chairman and CEO Peter Beetham - Co-Founder, President and COO Conference Call Participants Laurence Alexander - Jefferies Austin Moeller - Canaccord Matthew Venezia - Alliance Global Partners Operator Good day, and welcome to the Cibus Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator In ...

Cibus (CBUS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.90 per share. This compares to loss of $1.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 106.67%. A quarter ago, it was expected that this developer and licensor of plant traits for seed companies would post a loss of $0.81 per share when it actually produced a loss of $1.14, delivering a surprise of -40.7 ...